Use the hyperlinks, where available to access additional clinical trial information.
An Australasian, phase II, multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide and i.v. rituximab (poFCivR) tolerance in previously untreated elderly (= 65 years old) patients with chronic lymphocytic leukaemia (CLL) (Other IDs: ALLG CLL5).
Australasian Leukaemia and Lymphoma Group (ALLG)
This is a study investigating the tolerance of oral fludarabine, oral cyclophosphamide and i.v. rituximab (poFCivR) in previously untreated elderly (? 65 years old) patients with chronic lymphocytic leukaemia. Patients will be randomly assigned to one of three treatment groups: fludarabine and rituximab alone or fludarabine and rituximab with either 3 or 5 days of oral cyclophosphamide. The primary endpoint will be the proportion of patients completing 6 treatment cycles.